Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743494 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 794
- Enrollment target
NCT02743494 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 794 participants.
The verdict
NCT02743494, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 794 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
Interventions
- OTHER Placebo
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 794 participants |
| Start Date | 2016-07-14 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743494
The ClinicalTrials.gov registry entry for NCT02743494 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 794 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02743494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743494 about?
NCT02743494 is a clinical study titled "An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer". The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
What is the current status of trial NCT02743494?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 794 participants. The study started on 2016-07-14. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT02743494?
The interventions under investigation include: Placebo (OTHER), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02743494?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.